⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMT News
Sagimet Biosciences Inc. Series A Common Stock
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
globenewswire.com
SGMT
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
prnewswire.com
SGMT
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
globenewswire.com
SGMT
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
prnewswire.com
SGMT